Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Looking for a Growth Stock? 3 Reasons Why M/A-Com (MTSI) is a Solid Choice
Looking for a Growth Stock? 3 Reasons Why M/A-Com (MTSI) is a Solid Choice

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth

Here's Why Investors Should Give KNX Stock a Miss Now: https://staticx-tuner.zacks.com/images/articles/main/89/24730.jpg
Here's Why Investors Should Give KNX Stock a Miss Now

Knight-Swift Transportation KNX is facing mounting pressure from increased expenses. Tariff-related woes are also hurting the company’s prospects, making it an unattractive choice for investors’

PulteGroup to Boost Footprint by Debuting in the Cincinnati Market
PulteGroup to Boost Footprint by Debuting in the Cincinnati Market

PulteGroup, Inc. PHM is further reinforcing its market leadership in the Midwest with plans to expand its homebuilding operations into the Cincinnati market in Ohio.Building on its strong

Vertiv Gains From AI and Data Center Growth: A Sign for More Upside?
Vertiv Gains From AI and Data Center Growth: A Sign for More Upside?

Vertiv VRT is benefiting from the accelerating adoption of artificial intelligence (AI) and the growing demand for data centers globally. In the third quarter of 2025, Net sales increased 29% year

Dell Technologies AI Solutions Gain Momentum: A Sign for More Upside?
Dell Technologies AI Solutions Gain Momentum: A Sign for More Upside?

Dell Technologies DELL is benefiting from the growing demand for AI solutions, which has been a major growth driver for its success. In the second quarter of fiscal 2026, Dell Technologies reported

Will Amphenol's Aggressive M&A Push Unlock Its Next Growth Phase?
Will Amphenol's Aggressive M&A Push Unlock Its Next Growth Phase?

Amphenol APH is pursuing an aggressive acquisition strategy that is now delivering visible results. The strategy is significantly more relevant for investors evaluating the company's long-term

HIW's $223M Bet on 6Hundred at Legacy Union: Time to Buy the Stock?
HIW's $223M Bet on 6Hundred at Legacy Union: Time to Buy the Stock?

Highwoods Properties HIW is setting the stage for growth with the planned acquisition of 6Hundred at Legacy Union, a newly delivered 411,000-square-foot Class AA office tower in Charlotte’s Uptown

Earnings Estimates Rising for Jamf Holding (JAMF): Will It Gain?
Earnings Estimates Rising for Jamf Holding (JAMF): Will It Gain?

Jamf Holding (JAMF) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue

Earnings Estimates Rising for Allstate (ALL): Will It Gain?
Earnings Estimates Rising for Allstate (ALL): Will It Gain?

Allstate (ALL) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its

Here's Why Investors Should Give Canadian Pacific Stock a Miss Now
Here's Why Investors Should Give Canadian Pacific Stock a Miss Now

Canadian Pacific Kansas City Limited CP is facing mounting pressure from increased expenses. Tariff-related woes are also hurting the company’s prospects, making it an unattractive choice for

Alphabet: Buffett's Bet on Its Next Phase of Growth: https://www.marketbeat.com/logos/articles/med_20251118092056_alphabet-buffetts-bet-on-its-next-phase-of-growth.jpg
Alphabet: Buffett's Bet on Its Next Phase of Growth

Alphabet (NASDAQ: GOOGL) has gone from laggard to leader in the second half of the year, a shift that hasn’t gone unnoticed on Wall Street. After trailing the broader market and its Magnificent

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

Shares of Jazz Pharmaceuticals JAZZ rose nearly 21% on Monday after it announced positive top-line results from the late-stage HERIZON-GEA-01 study. This study evaluated different combination

Is RS2's New Visa Status a Game-Changer for Europe's Card Market?
Is RS2's New Visa Status a Game-Changer for Europe's Card Market?

Visa Inc. V is making waves in Europe as Beyond by RS2 steps up to become a Principal Issuing Member, a significant milestone that enhances V’s growing presence in the region’s rapidly expanding

Why Williams-Sonoma (WSM) Could Beat Earnings Estimates Again
Why Williams-Sonoma (WSM) Could Beat Earnings Estimates Again

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Williams-Sonoma (WSM), which belongs to

Beer Business Softness Deepens: Can Molson Coors Reignite Core Brands?
Beer Business Softness Deepens: Can Molson Coors Reignite Core Brands?

Molson Coors Beverage Company TAP is navigating one of the most challenging beer environments in recent years, as industry volume declines continue to weigh on overall performance. In 2025, U.S

Gorilla Technology Q3 Earnings Miss Estimates, Pipeline Increased: https://staticx-tuner.zacks.com/images/articles/main/32/128049.webp
Gorilla Technology Q3 Earnings Miss Estimates, Pipeline Increased

Gorilla Technology Group Inc. GRRR announced third-quarter 2025 adjusted EPS of 24 cents, missing the Zacks Consensus Estimate by 7.7% and decreasing 17.2% from the year-ago level.

Total revenues

Mission Produce's U.K. Hub Gains Traction: Is Europe the Next Big Bet?
Mission Produce's U.K. Hub Gains Traction: Is Europe the Next Big Bet?

Mission Produce, Inc.’s AVO growing momentum in the U.K. marks a strategic turning point for the company as it extends its avocado leadership into high-potential international markets. After years

All You Need to Know About PLBY Group (PLBY) Rating Upgrade to Buy
All You Need to Know About PLBY Group (PLBY) Rating Upgrade to Buy

PLBY Group, Inc. (PLBY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of

Ares Commercial Real Estate (ACRE) Upgraded to Buy: What Does It Mean for the Stock?
Ares Commercial Real Estate (ACRE) Upgraded to Buy: What Does It Mean for the Stock?

Ares Commercial Real Estate (ACRE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings

ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know

Investors might want to bet on ADC Therapeutics SA (ADCT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings

ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know

ANI Pharmaceuticals (ANIP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in

What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock

Jade Biosciences, Inc. (JBIO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings

All You Need to Know About Virgin Galactic (SPCE) Rating Upgrade to Buy
All You Need to Know About Virgin Galactic (SPCE) Rating Upgrade to Buy

Virgin Galactic (SPCE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of

Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know

Oric Pharmaceuticals, Inc. (ORIC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates

First Bank (FRBA) Upgraded to Strong Buy: Here's What You Should Know
First Bank (FRBA) Upgraded to Strong Buy: Here's What You Should Know

First Bank (FRBA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one